CLINICAL TRIALS PROFILE FOR TRIFAROTENE
✉ Email this page to a colleague
All Clinical Trials for TRIFAROTENE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02189629 ↗ | CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris | Completed | Galderma R&D | Phase 3 | 2015-02-23 | Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris. |
NCT02556788 ↗ | Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris | Completed | Galderma R&D | Phase 3 | 2015-11-01 | Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris. |
NCT02566369 ↗ | Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris | Completed | Galderma R&D | Phase 3 | 2015-11-30 | Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris. |
NCT03738800 ↗ | A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis | Terminated | Mayne Pharma International Pty Ltd | Phase 2 | 2019-05-01 | This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 90 day, safety, efficacy, and systemic exposure study followed by a 90 day open-label extension of trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar scale. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRIFAROTENE
Condition Name
Clinical Trial Locations for TRIFAROTENE
Trials by Country
Clinical Trial Progress for TRIFAROTENE
Clinical Trial Phase
Clinical Trial Sponsors for TRIFAROTENE
Sponsor Name